Core Insights - The meeting highlighted the rapid growth and diversification of commercial health insurance in China, driven by policy support and market demand, with an average annual compound growth rate exceeding 20% over the past decade [1][4] - The industry is expanding its coverage to include innovative treatments and technologies, with a projected total compensation amount for innovative drugs and devices reaching approximately 14.7 billion yuan by 2025, reflecting a compound annual growth rate of 70% [1][4] Group 1: Industry Development - The commercial health insurance sector has seen a significant increase in the number of products available, with over 11,000 medical insurance products currently on the market [1] - The industry has incorporated high-value treatments such as CAR-T therapy and proton therapy into its coverage, enhancing the service capabilities of health insurance [1][4] Group 2: Future Directions - The insurance industry is urged to align with national goals for health development, respond to market needs, and maintain the fundamental principles of commercial insurance while improving product offerings and service quality [2][4] - The China Insurance Industry Association is committed to strengthening industry self-discipline and enhancing collaboration with health, medical, and academic organizations to promote coordinated development and mutual benefits [2][5]

Core Insights - The Perfect (China) Co., Ltd. held its 2026 business launch conference in Shanghai, themed "Spring Blossoms," gathering nearly 4,000 guests to summarize past achievements and outline future directions [1] Group 1: Leadership and Vision - Chairman Gu Runjin emphasized the importance of mutual growth between individuals and enterprises, advocating for contributions to both national and global progress [6] - Vice Chairman Xu Guowei highlighted the trend of new consumption and entrepreneurship, stressing the need for personalized solutions in health and beauty [8] - CEO Peng Zhihong presented five key themes for 2025, focusing on strategic evolution and resilience in the face of changing external environments [10] Group 2: Initiatives and Collaborations - The "Perfect Youth Light Entrepreneurship Plan" was officially launched, aiming to create a platform for young entrepreneurs to transform ideas into business [15] - The "International Longevity Medical Research Institute Perfect Branch" was inaugurated, aiming to integrate scientific research with health products [24] - The company announced six major advantages for 2026, including brand expansion and new product development in the anti-aging sector [26] Group 3: Community and Recognition - The "Perfect Entrepreneurship Pioneer Award" recognized partners who have successfully navigated their entrepreneurial journeys, sharing their growth stories [17] - The fourth session of the Perfect China Business Development Committee was inaugurated, emphasizing collaboration and unity among partners [29] Group 4: Market Trends and Insights - The conference featured discussions on the resilience of the Chinese economy and the strategic importance of health consumption in the current global economic context [12] - The company is committed to promoting healthy lifestyles and has been actively involved in micro-ecological research to enhance product effectiveness [18][20]

烟台山医院党委委员、副院长孙涛详细介绍了医院的发展历程、学科建设与临床资源优势，全面展现了 医院作为区域医疗中心的综合实力。 扬子江药业集团山东鲁圣战术部负责人李淑敏围绕企业区域布局、核心优势作了介绍；山东鲁圣战术部 医学负责人仇荟然深度解析了战略合作的核心项目与实践路径，明确双方将在药物研发、临床试验、学 科共建、人才联合培养等领域展开全方位合作。 随后，双方共同签署战略合作协议，秉持"优势互补、共同发展"原则，在医药健康领域深耕细作，打造 院企协同创新标杆，共同推动区域医疗健康事业高质量发展。 齐鲁晚报·齐鲁壹点 孙淑玉 通讯员 潘峰 近日，烟台市烟台山医院与扬子江药业集团有限公司举行战略合作签约仪式，标志着双方正式开启优势 互补、资源整合的深度协同新篇章。 烟台市烟台山医院党委书记、院长姜俊杰在致辞中表示，医院始终秉持"开放共赢、互学互鉴"理念，始 终以"以患者为中心"的初心守护群众健康。扬子江药业作为全国首批创新型企业，践行"高质、惠民、 创新、至善"的核心价值观，以"三药并举"战略筑牢创新根基。双方发展理念高度契合，此次合作既是 响应国家"健康中国"战略的具体实践，更彰显了携手服务民生、共促行业发展 ...

Core Insights - Jilin Aodong Pharmaceutical Group Co., Ltd. has over 60 years of experience in the traditional Chinese medicine sector, focusing on the unique characteristics of the Changbai Mountain region and combining tradition with innovation to revitalize its brand [1][2] Group 1: Company Background and Development - The company originated from the state-owned Yanbian Dunhua Deer Farm established in 1957, forming a deep connection with local medicinal materials [1] - Jilin Aodong has built the largest GAP-certified deer breeding base in Asia and a medicinal material base in Changbai Mountain, establishing a resource library and database for local medicinal materials [1] - The company aims to become a leading enterprise in northern Chinese medicinal materials through a comprehensive industrial layout, including seedling nurseries and demonstration bases [1] Group 2: Technological Innovation and Quality Control - Jilin Aodong is breaking through traditional bottlenecks in Chinese medicine by integrating modern technology, transitioning from "experience-based manufacturing" to "intelligent manufacturing" [1] - The company has obtained 525 certifications for traditional Chinese medicine formula granules and has established an advanced traceability system for the entire industry chain to ensure medication safety [1][2] Group 3: Financial Strategy and Market Position - The dual-driven model of "healthcare + financial capital" supports the company's long-term strategy and adaptation to industry changes [2] - As the largest shareholder of GF Securities, Jilin Aodong also holds significant stakes in Shanghai Pharmaceuticals, Nanjing Pharmaceutical, and Liaoning Chengda, creating a capital synergy network across finance, pharmaceuticals, retail, and distribution [2] - The financial sector provides stable cash flow that supports the pharmaceutical business, ensuring high-quality development [2] Group 4: Future Outlook - Jilin Aodong plans to continue deepening research on the modernization of traditional Chinese medicine and extending its industrial chain layout [2] - The company aims to integrate into the "Healthy China" initiative, leveraging Changbai Mountain's medicinal materials, technological innovation, and capital collaboration to enhance its brand and contribute to the revitalization of the traditional Chinese medicine industry [2]

Group 1 - The core viewpoint of the article is the strategic partnership formed between LuNan Pharmaceutical Group and China National Pharmaceutical Group's Shaanxi and Qinghai subsidiaries, aimed at building a stable, efficient, and sustainable pharmaceutical supply chain in the Northwest region of China [1][3][4] - The "Changying Plan" emphasizes not only commercial sustainability but also a long-term mission to provide high-quality health products and services to the public, marking a significant step in LuNan's regional market strategy [3][4] - The partnership is expected to enhance market competitiveness and service capabilities in Shaanxi, leveraging the strong distribution network and professional logistics services of China National Pharmaceutical Group [3][4] Group 2 - The collaboration will focus on innovative projects such as hospital logistics and patient rehabilitation management, aiming to deepen the integration of brand, channel, and service [3][4] - In Qinghai, the partnership will address the unique challenges of drug accessibility and supply chain stability, with LuNan's diverse product line complementing the local network capabilities of China National Pharmaceutical Group [3][4] - The agreement is positioned to inject strong momentum into the high-quality development of the regional pharmaceutical industry and contribute to the "Healthy China" initiative [4]

Core Viewpoint - The establishment of the "Wang Wenbo Professor Longjiang Famous Doctor Studio" marks a significant advancement in orthopedic medical services in Harbin's Pingfang District, driven by collaboration between local hospitals and provincial medical resources [1][2]. Group 1: Collaboration and Expert Involvement - The signing ceremony for the cooperation agreement was attended by key officials, including the Deputy District Mayor and the Vice President of Harbin Medical University First Affiliated Hospital [1]. - Professor Wang Wenbo, a leading figure in orthopedics with over 30 years of experience, will lead the new studio, focusing on spinal and joint surgery [1]. Group 2: Objectives and Community Impact - The studio aims to address the weak capabilities of grassroots orthopedic services by leveraging provincial expert resources to meet community health needs [1][2]. - The initiative is part of a broader effort to enhance healthcare quality in the region, ensuring that residents can access high-level medical services locally [1][2]. Group 3: Implementation and Future Plans - The hospital plans to establish a regular communication mechanism to strengthen orthopedic talent development and standardize treatment processes [2]. - The collaboration will include expert consultations, health advisory services, and the creation of a regional orthopedic brand, reinforcing the "big illness does not leave the district" health strategy [2].

当直升机螺旋桨的轰鸣声在空中掠过，这场精心设计的瑞之恩生物科技"启航仪式"不仅是视觉上的震 撼，更是寓意着企业从实业深耕向资本市场迈出的跨越一步。 上午九点半，瑞之恩生物科技上市启动大会在国歌的旋律中正式开场。瑞之恩深耕的大健康产业，是关 乎国民健康这一国家战略，国歌的奏响，将企业的商业追求与更大的社会责任连接在了一起。在健康中 国战略背景下，瑞之恩的上市之路不仅是企业自身的发展需要，更是产业升级的必然选择。 上市启动大会奏国歌仪式 瑞之恩生物科技上市起航仪式 2026年1月16日，"瑞之恩生物科技上市启动大会"在北京华彬庄园圆满完成。新乡市红旗区区长刘怀斌 先生、瑞之恩生物科技董事长王新瑞先生、新乡红旗区先进制造业开发区管委会负责人李瑞祥先生、瑞 之恩生物科技首席执行官王帅先生、华为终端医疗健康合作伙伴代表王俊贤先生、北京尚融投资控股有 限公司管理合伙人、全国工商联并购公会副会长李聚合先生、尚融资本董事戚庆余先生、尚融资本投资 经理密林女士、步长制药健康事业部董事、总经理席冲先生、步长制药健康事业部华北大区总监李宁先 生、瑞之恩生物科技副总裁刘厚民先生、瑞之恩生物科技CFO屈展展女士、瑞之恩生物科技董事会秘 ...

据悉，健康城市蓝皮书坚持从专业角度对中国健康城市建设的最新成果进行集纳，已成为记录和反 映年度健康城市建设实践探讨和理论研究的重要载体，非常具有参考价值。 中国社会科学院社会科学文献出版社副社长梁艳玲表示，健康城市蓝皮书的出版是健康城市建设理 论创新和实践探索的重要成果，为提升人民健康水平和城市发展质量注入新的思想动力。 由中国医药卫生事业发展基金会、北京健康城市建设促进会联合举办的健康城市建设高质量发展会 议暨健康城市蓝皮书《中国健康城市建设研究报告(2025)》《北京健康城市建设研究报告(2025)》(以下 简称健康城市蓝皮书)发布会于1月17日在北京国际会议中心举行。来自国家有关部委、高校、企事业单 位、卫生医疗机构以及全国20多个省(自治区、直辖市)爱国卫生系统的相关领导、专家、学者以及健康 产业企业负责人300余人参加了会议。 会上，启动了2025健康城市蓝皮书发布暨2026健康城市蓝皮书编纂出版项目，并联合发布"十五 五"促进健康中国、健康城市建设五大重点项目。 中国健康城市研究院院长、健康城市蓝皮书主编王鸿春研究员表示，下一步要围绕健康中国战略实 施和健康中国18个专项行动，组织编纂健康中国、健 ...

Core Viewpoint - The article emphasizes the importance of population quality development as a fundamental aspect of China's modernization, highlighting the need for a comprehensive strategy to enhance human resources and address demographic challenges [1]. Group 1: Understanding Population Quality Development - The comprehensive quality of the population has significantly improved, with life expectancy projected to reach 79.0 years by 2024, and infant mortality rates dropping to 2.5‰ [2]. - Education has seen remarkable advancements, with a gross enrollment rate of 92.0% in preschool education and over 2.5 billion people having received higher education, making China the country with the highest number of university graduates annually [2]. Group 2: Population Scale and Structure - China's total population peaked at 1.413 billion in 2021 and is projected to decrease to 1.405 billion by the end of 2025, while still remaining the second-largest globally [3]. - The aging population is a significant issue, with 297 million elderly individuals in 2023, expected to rise to 323 million by 2025, indicating a deepening of the aging society [3]. Group 3: Regional Population Dynamics - The movement of people, including migrant workers, has been a driving force for economic growth, maintaining a high level of population mobility that enhances urbanization and labor participation [4]. Group 4: Key Tasks for Promoting Population Quality Development - Enhancing population quality is crucial, with a focus on health and education, and the implementation of a comprehensive support system for marriage and childbirth to stabilize population numbers [5][6]. - Policies such as childcare subsidies, tax deductions, and improved maternity leave are essential to reduce the costs associated with childbirth and child-rearing [7]. Group 5: Labor Resource Optimization - Improving labor supply and employment capabilities is vital for economic development, with a focus on stabilizing employment rates and enhancing vocational training [8]. - The strategy includes promoting flexible employment and ensuring the rights of new employment forms, while also addressing the aging workforce by gradually raising the retirement age [8]. Group 6: Addressing Population Aging - A comprehensive approach to aging is necessary, including the development of a multi-tiered pension system and enhancing healthcare services for the elderly [9]. - The article advocates for the growth of the silver economy and the integration of elderly care services to improve the quality of life for older adults [9].

来源：环球网 为积极应对冬春季流感传播风险，提升公众尤其是青少年的健康防护意识，近日，中国青年出版总社在 北京青年宫开启了青少年预防流感健康科普公益活动。该活动旨在通过持续、系统的科普教育，将专业 流感防治知识转化为公众易于理解、乐于接受的形式，助力"健康中国"建设在校园落地生根。 作为本次活动的公益支持方，罗氏制药中国企业事务与传播部副总裁隆伟利女士在接受采访时表 示："罗氏连续两年深度参与此项公益，既是践行"先患者之需而行"的企业理念，也是深耕中国、共建 公共卫生体系的长期承诺。作为创新生物医药企业，罗氏致力于扮演"科学连接者"的角色，积极履行社 会责任，以实际行动响应"健康中国"战略。具体举措上，罗氏聚焦于构建多元科普体系，支持合作伙伴 以丰富形式开展活动，并携手临床专家共同推动专业知识生动走进校园。未来，公司计划将成熟的校园 科普模式系统化推广至更多基层学校与社区，借助"线上+线下"方式，助力构建覆盖更广、反应更及时 的社会化流感防护网络。" 本届行动延续"医教结合、科普先行"的理念，注重权威性、趣味性与实用性的平衡。主办方表示，希望 通过系统化、常态化的公益科普，真正实现"教育一个孩子，带动一个家庭 ...